​Study Background

Understanding pathogenesis of histiocytic diseases is prerequisite to improving clinical and therapeutic strategies. Biological samples collected will be used to investigate genes and proteins that may better define the biology of histiocytic diseases. Additionally, biomarker discovery experiments may identify biomarkers that may be utilized as diagnostic or therapeutic targets in future protocols. Tissue will be collected, processed and stored with correlated clinical data to support specific aims as well as future research initiatives. This will be a companion biology study to NACHO clinical trials.

​Primary Objective

To determine the biological basis of histiocytic diseases and evaluate clinically relevant biomarkers.

​Study Investigators

Carl Allen, MD, PhD, Principal Investigator
Texas Children’s Cancer Center/Baylor College of Medicine, Houston, TX USA

Michelle Hermiston, MD, PhD, Co-Investigator
University of California San Francisco School of Medicine, San Francisco, CA USA

Michael Hogarty, MD, Co-Investigator
The Children’s Hospital of Philadelphia/University of Pennsylvania, Philadelphia, PA USA

Michael B. Jordan, MD, Co-Investigator
Cincinnati Children's Hospital Medical Center, Cincinnati, OH USA

Miriam Merad, MD, PhD, Co-Investigator
Icahn School of Medicine at Mount Sinai, New York, NY USA

D. Williams Parsons, MD, PhD, Co-Investigator
Baylor College of Medicine/Texas Children's Cancer Center, Houston, TX USA

Carlos Rodriguez-Galindo, MD, Co-Principal Investigator
St. Jude Children's Research Hospital, Memphis, TN USA

Barrett Rollins, MD, PhD, Co-Investigator
Harvard Medical School/Dana-Farber Cancer Institute, Boston, MA USA